[Betamed in the treatment of psychogenic disorders with a somatic component].
52 patients with acute neurotic anxious and psychosomatic syndromes or chronic anxious and vegetative neuroses were treated orally with the combination drug Betamed (1 tablet contain 60 mg bupranolol and 2.5 mg diazepam). The optimum daily dosage are 2 to 3 tablets; duration of treatment ranged from 2 to 12 weeks. The most responsive target symptoms are psychogenic disorders of the cardiovascular system, anxiety and insomnia, while no antidepressive effect was observed. Clinical improvement is often observed 2 to 3 weeks after the onset of treatment, and dosage reduction is possible frequently. Rarely observed side effects are minimal and mainly occur within one week after onset of treatment. Controls performed 2 to 4 weeks after discontinuation of treatment revealed reactivation of symptoms only in some patients with chronic anxiety and vegetative syndromes. In addition to the easy application and excellent tolerance of the combination drug emphasis is given on the minimal danger of drug dependence.
D000293:Adolescent; D000328:Adult; D000368:Aged; D001008:Anxiety Disorders / Q000188:drug therapy*; D002046:Bupranolol / Q000009:adverse effects / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D003975:Diazepam / Q000009:adverse effects / Q000627:therapeutic use*; D004334:Drug Administration Schedule; D004338:Drug Combinations; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009497:Neurotic Disorders / Q000188:drug therapy; D011412:Propanolamines / Q000627:therapeutic use*; D011602:Psychophysiologic Disorders / Q000188:drug therapy*; D012894:Sleep Stages / Q000187:drug effects; D014717:Vertigo / Q000139:chemically induced
D004338:Drug Combinations; D011412:Propanolamines; D002046:Bupranolol; D003975:Diazepam
Betamed in der Behandlung psychogener Störungen mit Somatisierungstendenz.